Sézary cells (SC) (synonyms: mycosis cell, Lutzner cell, cerebriform lymphocytes, Atypia Cellules Monstreuses or monster cell 1, 2 ) are atypical lymphocytes with a grooved or cerebriform nucleus seen both in tissue and blood. They are characteristically seen in cutaneous T cell lymphomas including mycosis fungoides (MF). The Sézary cell is named after the French dermatologist Sézary A ).
3 Sézary and Bouvrain described the leukemic variant of MF in 1938 where they identified the monster cells with atypical features. This variant is now known as Sézary syndrome. In 1968, Lutzner and Jordan 4 described the ultrastructural details of Sézary cells.
MORPHOLOGY
Three variants of Sézary cell are identified based on its size. The 'small cells' are less than 12 microns in diameter, 'large cells' are more than 12 microns and the 'very large cells' are more than 14 microns. 5 The nucleus, occupying at least four fifths of the cell, shows a variable surface contour ranging from mild indentations to gross cerebriform shape (Figure 1 , 2).
6
The nuclear chromatin is condensed in a patchy distribution beneath the nuclear membrane. The nucleoli may be prominent. The cytoplasm is sparse
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and appears as a narrow rim around the nucleus. Mitochondria, often appearing clumped, rough endoplasmic reticulum, polysomes and cytoplasmic fibrils are seen. The cytoplasmic fibrils appear serpentine on electron microscopic examination.
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IMMUNOHISTOCHEMISTRY
Sézary cell is a malignant CD4+ helper T cell of the T helper 2 subset. 8 It produces cytokines (IL-4, IL-5 and IL-10) that enhance the differentiation and activation of eosinophils and suppress T helper 1 activity. The early lesion of mycosis fungoides retains the expression of both majority T cell markers like CD7 and Leu-8 (CD62L) which are present on most mature non-neoplastic T cells and pan T cells markers like CD2,CD3 and CD5 which are present on all mature non-neoplastic T cells. As lesions progress the earliest marker lost is a majority T cell antigen. Majority T cell markers may be lost in both MF and in 10-20% of inflammatory dermatoses. Pan T cell markers are less commonly lost in MF, but if they are lost then we can exclude the possibility of it being an inflammatory dermatosis. The absence of CD7 or Leu-8 within epidermis has been observed in mycosis fungoides, a feature absent in inflammatory lesions.
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Dipeptidyl peptidase IV (CD26) is found to be absent on circulating neoplastic cells in Sézary syndrome. The level of CD4+ CD26-T cell subpopulation correlates with the extent of peripheral blood involvement. 13 Recently CD158k marker has been demonstrated on Sézary cells.
14 This marker may prove useful as a tool for evaluation of circulating tumoral burden and in the follow up of patients with Sézary syndrome.
HISTOGENESIS
The site of origin of Sézary cell has not been determined. Large numbers of these cells are seen in the dermis in MF and Sézary syndrome.
Epidermotropism is noted more markedly in mycosis fungoides as compared to Sézary syndrome. It has been shown that these atypical cells are in fact actively dividing in the dermis itself, the dermis forming a home to these cells. The cells appearing in the peripheral blood are probably an overspill phenomenon. 15 The observations that these cells cannot be demonstrated in abnormal amounts in bone marrow and that they tend to disappear when skin lesions resolve support this theory.
It is believed that the evolution of mycosis fungoides starts with the aggregation of circulating T helper cells in the papillary dermis. This is followed by a selection phase where cells with a T helper 2 cytokine profile predominate and are then transformed into a clonal population by various cytokines. The final stage is the dissemination phase in which the neoplastic cells dedifferentiate without the need of the skin microenvironment. The critical step in the cascade seems to be the commitment to the T helper 2 subtype. Once switched to the T helper 2 profile the cytokines produced suppress immunosurveillance by the cytotoxic T lymphocytes and the natural killer cells allowing for unremitting stimulation of the T helper cells by the autocrine loop and by antigen presenting cells.
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A higher incidence of Sézary syndrome is seen with occupational exposure to industrial solvents and in those employed in the petrochemical, textile, manufacturing and construction industries.
17 Recently, the Human T cell lymphotropic virus I /II have been implicated although molecular analyses have been inconclusive.
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LABORATORY DIAGNOSIS
In blood smear Sézary cells appear as mononuclear cells with grooved nuclei and cytoplasmic vacuoles, which can often be stained with Periodic Acid Schiff reagent. Glycogen is responsible for staining in some, but not in all of the vacuoles.
19 These cells can also be recognized by Giemsa or Wright staining methods. Some Sézary cells are the size of normal lymphocyte while others are much larger. Based on the 21 It must be realized that it is not necessary to have a raised total lymphocyte count for the diagnosis to be made and in such situations unless the tail of the smear or the buffy coat is specifically examined for the atypical cells, the diagnosis may easily be missed. At least 100 lymphocytes are counted to determine the percentage of cells showing Sézary phenomenon. Lutzner, et al compared the ultrastructure of the abnormal cells in the skin, lymph nodes and peripheral blood of patients with Sézary syndrome and found that the cells were similar.
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Ultrastructural morphometry has been used to distinguish Sézary cells in blood from normal lymphocytes and reactive lymphocytes.
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CLINICAL SIGNIFICANCE
In mycosis fungoides the Sézary cell is considered malignant based on following criteria: 1. They are present in skin lesions and viscera 2. Have abnormal number of chromosomes and abnormal kar yotypes including marker chromosomes
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Diagnosis of Sézary syndrome as originally described requires the presence of the triad of erythroderma, lymphadenopathy and 10% or more of atypical mononuclear cells in the peripheral smear. Many experts now consider a circulating Sézary cell count which exceeds 1000 cells/cumm as characteristic of Sézary syndrome and the prognosis to be worse in patients with circulating Sézary cell counts of >5% of total lymphocyte count. The term pre Sézary syndrome is used if cell count is < 1000 cells/cumm with erythroderma, although others believe that presence of Sézary cell by itself is significant irrespective of the number.
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Blood criteria to define Sézary syndrome as recently proposed by ISCL are the following:
• Although Sézary cell is the pathological hallmark of cutaneous T cell lymphoma, its significance has been brought into dispute as similar atypical mononuclear cells have been described in a variety of other skin disorders ( Table 1 ). The conditions include lichen planus, discoid lupus erythematosus, psoriasis, vasculitis, actinic keratosis, 6 actinic reticuloid,
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dilantin hypersensitivity syndrome and erythrodermic follicular mucinosis. Whether CD4+ CD7-T cells present in the epidermis and the dermis represent the neoplastically transformed cell population can be determined using the panel of antibodies to the variable regions of T cell receptor (TCR beta chain). 9 Although chromosomal characteristics/DNA content of the Sézary look-alike cells in benign dermatoses is yet to be studied, such studies of Sézary cell reveal abnormal number of chromosomes and abnormal karyotypes pointing towards its malignant nature. 
